Clinical trial NCT05518279: Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures
Official title: Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures: A Prospective, Randomized, Double-blinded, Placebo Controlled Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Hip Fractures
Blood Loss
Keywords: hip fracture
blood loss
tranexamic acid
Lead sponsor: Henry Ford Health System
Sponsor class: OTHER
First posted: 2022-08-26
Enrollment: 0
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is a prospective, randomized, double blinded, placebo controlled trial that aims to investigate the hypothesis that early administration of tranexamic acid (TXA) following diagnosis of hip fracture will lower pre and postoperative blood loss and transfusion rates. Patients who present to the hospital with a hip fracture will be recruited and randomized into two treatment arms. The treatment group will receive 1950mg of oral TXA (three tablets, 650 mg each) and the control group will be given three tablets of oral placebo while in the Emergency Department. Patients will then be admitted to the Orthopaedic Trauma service and treated surgically with cephalomedullary nail, hemiarthroplasty, sliding hip screw, percutaneous screws, or total hip arthroplasty.

Detailed description: There remains a high incidence of blood transfusion in patients following hip fractures. Tranexamic acid (TXA) has well-studied efficacy in decreasing blood loss and transfusion requirements in the context of general trauma, as well as several elective orthopaedic procedures. Although blood is lost in hip fracture surgery itself, it is also known that there is significant blood loss pre-operatively following the hip fracture event, particularly in extracapsular hip fractures. A prospective, randomized, double blinded, placebo controlled trial will elucidate the roll of early administration of TXA in a population of patients who sustain hip fractures. The study aims to investigate the hypothesis that early administration of TXA following diagnosis of hip fracture will lower pre and postoperative blood loss and transfusion rates. There will be two treatment arms in the study. The treatment group will be given 1950mg of oral TXA (3 tablets, 650mg each) in the emergency department following diagnosis of hip fracture. Those randomized to the control group will be given 3 tablets of oral placebo in the emergency department following diagnosis of hip fracture. Patients will then be admitted to the Orthopaedic Trauma service and treated surgically with cephalomedullary nail, hemiarthroplasty, sliding hip screw, percutaneous screws, or total hip arthroplasty.

Eligibility criteria: Inclusion Criteria:

* Age over 50
* Clinical diagnosis of acute femoral neck, intertrochanteric or subtrochanteric femur fracture

Exclusion Criteria:

* anticoagulant use at time of admission to emergency department
* documented allergy to tranexamic acid
* history of deep vein thrombosis or pulmonary embolism
* hepatic dysfunction (aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 60)
* renal dysfunction (Creatinine \> 1.5 or Glomerular Filtration Rate \< 30)
* active coronary artery disease (event within 12 months)
* history of cerebral vascular accident within 12 months
* presence of drug eluting stent
* color blindness
* active cancer
* coagulopathy (International Normalized Ratio \> 1.4, Partial Thromboplastin Time \> 1.4 times normal, platelets \< 50,000)

Primary outcomes:
measure: Blood transfusion rate
timeFrame: This outcome will be recorded daily from the time of admission to the Emergency Department through the time of discharge from the hospital, assessed up to 7 days.
measure: Hemoglobin Level
timeFrame: This outcome will be recorded daily from the time of admission to the Emergency Department to the time of discharge from the hospital, up to 7 days.
Secondary outcomes:
measure: Estimated blood loss
timeFrame: Starting at time of surgical incision and will end once the surgery is completed.
measure: Frequency of adverse events.
timeFrame: From time of admission to the Emergency department up to 12 months after the date of surgery. Outcome measure will be recorded daily while participant is hospitalized and monthly after discharge from the hospital.
Other outcomes:
Locations:
Study officials:
affiliation: Henry Ford Hospital Department of Orthopaedic Surgery
name: Trent Guthrie, MD
role: PRINCIPAL_INVESTIGATOR
References: